Zinzino Sales Surge Masks Faun Pharma Decline

Event summary

  • Zinzino group revenue increased 51% year-over-year to SEK 3,344.5 million for full-year 2025.
  • Q4 2025 revenue grew 46% to SEK 1,042.4 million, with December sales up 35% to SEK 334.4 million.
  • Faun Pharma’s external sales significantly decreased, falling 51% to SEK 50.4 million for the year.
  • Revenue growth was geographically uneven, with North America and Asia-Pacific exhibiting the strongest expansion (172% and 254% respectively).

The big picture

Zinzino’s impressive revenue growth highlights the effectiveness of its direct sales model and geographic expansion strategy. However, the significant decline in Faun Pharma’s performance introduces a potential strategic overhang and could signal a broader portfolio review. The company's ability to maintain its high growth trajectory will depend on navigating regional market dynamics and addressing the performance gap within its subsidiaries.

What we're watching

Subsidiary Risk
The stark contrast in performance between Zinzino and Faun Pharma raises questions about the strategic fit and potential for further divestiture or restructuring within the group.
Regional Sustainability
While North America and Asia-Pacific demonstrate impressive growth, the sustainability of these rates, particularly in North America, needs to be assessed against potential market saturation and increased competition.
Growth Dependency
Zinzino's reliance on rapid geographic expansion to drive overall revenue growth creates a vulnerability if expansion slows or encounters regulatory or logistical challenges in new markets.

Related topics

Revenue Growth